Is Mirikizumab included in medical insurance?

Mirikizumab (Mirikizumab)-Omvoh is a specific monoclonal antibody against interleukin-23 (IL-23), mainly used to treat ulcerative colitis (UC) and other autoimmune diseases. As a biological agent, militizumab reduces the inflammatory response by inhibiting the activity of IL-23, thereby improving the clinical symptoms of patients with ulcerative colitis.

Militizumab has shown significant efficacy in the treatment of ulcerative colitis. According to clinical trial data, the drug can effectively reduce patients' symptoms such as abdominal pain, bloody stools, urgency to defecate, and increased stool frequency. At the same time, militizumab also helps restore the mucosal integrity of the intestine and improves quality of life. Due to its specific mechanism of action, militizumab is considered a treatment option with a good safety profile and a relatively low risk of serious side effects compared to traditional immunosuppressants or biologics.

In addition to ulcerative colitis, militizumab has shown promise in studies of other autoimmune diseases, such as psoriasis and Crohn's disease. The expansion of these indications makes militizumab have greater prospects in clinical application.

Regarding the issue of medical insurance coverage, Militizumab has been approved in many countries and regions, but it has not yet been launched in the Chinese market. Therefore, this drug is currently not covered by China’s medical insurance. Inclusion in medical insurance usually requires evaluation by relevant departments, including consideration of clinical effects, safety, economics and other aspects. Because the price of militizumab can be high, patients may face a financial burden in obtaining the drug. Therefore, it is very important to pay attention to the dynamic changes in medical insurance policies, and patients should actively communicate with medical institutions to obtain the latest medical insurance information.

Reference materials:https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-omvohr-mirikizumab-mrkz-crohns-disease